uniQure stock: H.C. Wainwright cuts target to USD 65
Published on 11/22/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst Cuts Target, Keeps Buy
- H.C. Wainwright retained its Buy rating on uniQure.
- The analyst cited greater uncertainty after four-year data for ifezuntirgene inilparvovec.
- The firm still said the totality of evidence supports accelerated approval.
H.C. Wainwright cut its price target for uniQure from USD 80 to USD 65 on November 18, while retaining a Buy rating on the shares. Markets Insider reported that the analyst cited increased uncertainty following four-year data for ifezuntirgene inilparvovec.
Lower Target, Unchanged Rating
The USD 15 reduction represents an 18.75 percent cut to the previous target. H.C. Wainwright nevertheless kept its Buy rating and said the totality of the evidence supports accelerated approval.
The analyst action lowers the firm's valuation assumption while preserving its positive stance on the therapy's regulatory prospects. The company-specific catalyst remains the evidence package for ifezuntirgene inilparvovec and its implications for the accelerated-approval process.
uniQure Company Facts
- Company: uniQure N.V.
- ISIN: NL0010696654
Broader market developments are covered in Current market reports.
